Pro-inflammatory modification of cancer cells microsurroundings increases the survival rates for rats with low differentiated malignant glioma of brain.


Journal

International review of neurobiology
ISSN: 2162-5514
Titre abrégé: Int Rev Neurobiol
Pays: United States
ID NLM: 0374740

Informations de publication

Date de publication:
2020
Historique:
entrez: 26 5 2020
pubmed: 26 5 2020
medline: 4 6 2021
Statut: ppublish

Résumé

Glioblastoma multiforme (GBM) is one of the most aggressive human brain tumors. The prognosis is unfavorable with a median survival of 15 months. GBM aggressive nature is associated with a special phenotype of cancer cells that develops because of the transforming growth factor β (TGF-β). The study was aimed at providing experimental justification in vivo of a possibility to suppress TGF-β production in a tumor via pro-inflammatory modification of cancer cell microenvironment, using CD45+ mononuclear cells of the red bone marrow. The experiment used animals with transplanted C6 glioma. The animals were divided into 4 groups: (I) control (N=60); (II) group of rats (N=30) that received granulocyte colony-stimulating factor (G-CSF) to recruit CD45+ bone marrow mononuclear cells into their systemic circulation (G-CSF group); (III) group of rats (N=30) that received pro-inflammatory therapy to trigger systemic inflammatory reaction by injecting bacterial lipopolysaccharides (LPS) and interferon-γ (IFNγ); (IV) rats (N=30), stimulated with G-CSF, followed by pro-inflammatory therapy. Stereotaxic modeling of a brain tumor in experimental animals, as well as a combination of morphological, immunocytochemical analyses and immunosorbent assay were used. TGF-β1 production in the tumor tissue resulted being inversely proportional to the intensity of proliferation processes and directly proportional to the size of necrosis areas, peaking on the 28th day of the experiment. Stimulation of experimental animals with G-CSF recruits CD45+ mononuclear stem and progenitor cells into the systemic circulation of experimental animals with C6 glioma, accompanied by intensification of microglial proliferation in the tumor and infiltration of the tumor tissue with microglial cells. Pro-inflammatory therapy against G-CSF stimulation results in polarization of microglia/macrophages population together with intensified antigen presentation, lower production of TGF-β and IL10, increased synthesis of pro-inflammatory cytokines TNFα and IL1 in the tumor lesion and adjacent brain matter, remodeling of tumor matrix and higher survival rates for the experimental animals. Pro-inflammatory inflammatory modification of cancer cell microenvironment suppresses TGFβ production in a tumor and increases survival rates of the rats with transplanted poorly differentiated malignant brain glioma.

Identifiants

pubmed: 32448611
pii: S0074-7742(20)30058-1
doi: 10.1016/bs.irn.2020.03.027
pii:
doi:

Substances chimiques

Cytokines 0
Tgfb1 protein, rat 0
Transforming Growth Factor beta1 0
Granulocyte Colony-Stimulating Factor 143011-72-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

253-279

Informations de copyright

© 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare there are no conflicts of interests.

Auteurs

Sergei Zaitsev (S)

Department of Fundamental Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia.

Hari Shanker Sharma (HS)

International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, University Hospital, Uppsala University, S-75185 Uppsala, Sweden.

Aruna Sharma (A)

International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, University Hospital, Uppsala University, S-75185 Uppsala, Sweden.

Igor Manzhulo (I)

Department of Fundamental Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia; Laboratory of Pharmacology, National Scientific Center of Marine Biology, Far East Branch of the Russian Academy of Sciences, Vladivostok, Russia.

Alexander Polevshchikov (A)

Institute of Experimental Medicine, Dept. of Immunology, Saint-Petersburg, Russia.

Igor Kudriavtsev (I)

Institute of Experimental Medicine, Dept. of Immunology, Saint-Petersburg, Russia.

Yuri Khotimchenko (Y)

Department of Fundamental Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia; Laboratory of Pharmacology, National Scientific Center of Marine Biology, Far East Branch of the Russian Academy of Sciences, Vladivostok, Russia.

Oleg Pak (O)

Medical Center, Far Eastern Federal University, Vladivostok, Russia.

Andrey Bryukhovetskiy (A)

NeuroVita Clinic of Interventional and Restorative Neurology and Therapy, Moscow, Russia.

Igor Bryukhovetskiy (I)

Department of Fundamental Medicine, School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia; Laboratory of Pharmacology, National Scientific Center of Marine Biology, Far East Branch of the Russian Academy of Sciences, Vladivostok, Russia; Medical Center, Far Eastern Federal University, Vladivostok, Russia. Electronic address: igbryukhovetskiy@gmail.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH